Companies Avenue Therapeutics, Inc
Avenue Therapeutics CEO salary & total pay, FY2025: $447K
Avenue Therapeutics (ATXI) CEO salary, fiscal 2025: Alexandra MacLean was paid a salary of $420,000 and $447,307 in total compensation. Free brief. Every figure links to the company’s own filing.
Velarion Intel: free for 3 days, no card →Email me Avenue Therapeutics, Inc’s executive pay brief as a PDF
You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.
After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.
Alexandra MacLean's complete compensation dossier
A PDF and a CSV sent to your email: Alexandra MacLean's pay in every fiscal year Avenue Therapeutics, Inc reported it, line by line, with Alexandra MacLean's equity grants and Avenue Therapeutics, Inc's disclosed peer group where the company discloses them. Every row is cited to its filing.
See an example →CEO pay, last three years
- $1,213,200FY2023
- $840,100FY2024
- $447,307FY2025
CEO total pay was $447,307 in fiscal 2025, down from $840,100 in fiscal 2024.
FY2025: salary $420,000 · bonus $0 · stock awards $13,307 · option awards $0
Executives and directors
Frequently asked questions
Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.
Full detail
Every table from the filing. Open any section.
Summary compensation table
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Alexandra MacLean | $420,000 | $0 | $13,307 | $0 | $0 | $0 | $14,000 | $447,307 |
| Chief Executive Officer | ||||||||
| David Jin | 0 | 0 | 7,984 | 0 | 0 | 0 | 0 | 7,984 |
| Interim Chief Financial Officer and Chief Operating Officer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
Three-year trend — total compensation per named executive
| Named executive officer | FY2025 total | FY2024 total | FY2023 total | Δ FY2024→2025 |
|---|---|---|---|---|
| Alexandra MacLean | $447,307 | $840,100 | $1,213,200 | ↓ −392,793 |
| David Jin | 7,984 | 155,350 | 260,000 | ↓ −147,366 |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Incentive-plan design — the Compensation Discussion & Analysis
The Company provides compensation to its named executive officers based on at-will employment terms, with the CEO eligible for a discretionary annual bonus and equity awards granted primarily through subsidiary plans prior to acquisition. The compensation structure relies on base salary, discretionary bonuses, and equity incentives such as RSUs and options, with no formal written employment contracts in place.
| CEO STI target (% of salary) | — |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | true |
| Anti-hedging | true |
| Anti-pledging | false |
Equity grants and outstanding awards
Grants of plan-based awards — fiscal year 2025
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| David Jin | RSU | — | — | — | 266,147 | — | $7,984 |
| Alexandra MacLean | RSU | — | — | — | 443,578 | — | 13,307 |
Vehicle mix — grant-date fair value by award type
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| David Jin | $7,984 | $0 | $0 | 0.0% |
| Alexandra MacLean | 13,307 | 0 | 0 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
Outstanding equity awards at fiscal year-end 2025
| Executive | Award | Exercisable | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|---|
| Alexandra MacLean | Option | 8,004 | 2,664 | 85.5 | — |
| Alexandra MacLean | RSU | — | 42,500 | — | 28,909 |
| David Jin | Option | 2,500 | 834 | 85.5 | — |
| David Jin | RSU | — | 16,250 | — | 11,053 |
Director compensation
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jay Kranzler, M.D., PhDNot independent · Board Chair | $60,000 | — | $0 | — | $50,000 | $110,000 |
| Neil HerskowitzIndependent | 60,000 | — | 0 | — | 0 | 60,000 |
| Curtis OltmansIndependent | 50,000 | — | 0 | — | 0 | 50,000 |
| Faith CharlesIndependent | 50,000 | — | 0 | — | 0 | 50,000 |
| Lindsay A. Rosenwald, M.DNot independent | 0 | — | 0 | — | 0 | — |
Board fee structure and ownership guideline
| Annual cash retainer | $50,000 |
|---|---|
| Annual equity retainer | — |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | 10,000 |
| Stock ownership guideline | — |
Total cost of the board
| Component | FY2025 |
|---|---|
| Cash retainers and fees | $220,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $50,000 |
| Total cost of the board | $270,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Peer group, and who names Avenue Therapeutics as a peer
Companies that benchmark against ATXI
No companies currently name ATXI as a compensation peer in their most recent disclosure.
This is the complete answer, not a partial one — the list is never padded.
Chief executive pay against the peer group
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Avenue Therapeutics, Inc | 2025 | Alexandra MacLean | $420,000 | $13,307 | $0 | $0 | $447,307 |
Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Say-on-pay history and pay ratio
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2025 | 2025-12-30 | — | — | — | — | — |
| 2024 | 2024-06-24 | — | — | — | — | — |
| 2023 | 2023-06-22 | 9,541,965 | 128,472 | 32,597 | 98.34% | Passed |
| 2021 | 2021-12-16 | — | — | — | — | — |
| 2020 | 2020-06-16 | — | — | — | — | — |
| 2019 | 2019-06-19 | — | — | — | — | — |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.
Say-on-pay — history, company’s computation
| Meeting year | Meeting date | Approval — company’s computation |
|---|---|---|
| 2025 | 2025-12-30 | —a |
| 2024 | 2024-06-24 | —b |
| 2023 | 2023-06-22 | 98.34%c |
a. Voting standard not stated in the filing.
b. Voting standard not stated in the filing.
c. Approved under the standard stated in the filing — “The affirmative vote of a majority of the shares present, virtually at the Annual Meeting or by proxy, and entitled to vote at the Annual Meeting is required to approve the compensation of our named executive officers. || Abstentions will have the same effect as a vote "AGAINST" this proposal.”.
Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
Insider trades since the proxy
No insider equity transactions reported since the proxy statement.
Sources (16 citations)
Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.
- Section 01, Alexandra MacLean. 10-K, filed 2026-03-30. Section “Executive Compensation” · page 71. As printed: 447,307. View filing ↗
- Section 01, David Jin. 10-K, filed 2026-03-30. Section “Executive Compensation” · page 71. As printed: 7,984. View filing ↗
- Section 03, David Jin RSU. DEF 14A, filed 2026-03-30. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 03, Alexandra MacLean RSU. DEF 14A, filed 2026-03-30. Section “Executive Compensation” · grants of plan-based awards table. View filing ↗
- Section 08, Jay Kranzler, M.D., PhD. DEF 14A, filed 2026-03-30. Section “Director Compensation”. As printed: 110,000. View filing ↗
- Section 08, Neil Herskowitz. DEF 14A, filed 2026-03-30. Section “Director Compensation”. As printed: 60,000. View filing ↗
- Section 08, Curtis Oltmans. DEF 14A, filed 2026-03-30. Section “Director Compensation”. As printed: 50,000. View filing ↗
- Section 08, Faith Charles. DEF 14A, filed 2026-03-30. Section “Director Compensation”. As printed: 50,000. View filing ↗
- Section 08, Lindsay A. Rosenwald, M.D. DEF 14A, filed 2026-03-30. Section “Director Compensation”. As printed: —. View filing ↗
- Section 06, 2025 vote. Form 8-K, filed 2025-12-31. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2024 vote. Form 8-K, filed 2024-06-26. Item 5.07 · say-on-pay result. As reported: —. View filing ↗
- Section 06, 2023 vote. Form 8-K, filed 2023-06-26. Item 5.07 · say-on-pay result. As reported: 98.34% (votes for as printed: 9,541,965). View filing ↗
- Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
- Section 03b vehicle mix (computed). Computed. RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).
- Section 09b board cost (computed). Computed. Cash 220,000 + equity 0 + all other 50,000 = 270,000, summed across the director compensation table rows.
- Avenue Therapeutics, Inc (subject), Section 10b CEO total. 10-K, filed 2026-03-30. CEO total compensation as printed in Avenue Therapeutics, Inc's own proxy. As printed: 447,307. View filing ↗